Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up
- PMID: 24808435
- PMCID: PMC4463272
- DOI: 10.5152/dir.2014.13319
Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up
Abstract
Purpose: We aimed to determine the natural history of small index lesions identified on multiparametric-magnetic resonance imaging (MP-MRI) of the prostate by evaluating lesion-specific pathology and growth on serial MP-MRI.
Materials and methods: We performed a retrospective review of 153 patients who underwent a minimum of two MP-MRI sessions, on an institutional review board-approved protocol. Index lesion is defined as the lesion(s) with the highest cancer suspicion score based on initial MP-MRI of a patient, irrespective of size. Two study cohorts were identified: (1) patients with no index lesion or index lesion(s) ≤7 mm and (2) a subset with no index lesion or index lesion(s) ≤5 mm. Pathological analysis of the index lesions was performed following magnetic resonance/ultrasound fusion-guided biopsy. Growth rate of the lesions was calculated based on MP-MRI follow-up.
Results: Patients with small index lesions measuring ≤7 mm (n=42) or a subset with lesions ≤5 mm (n=20) demonstrated either benign findings (86.2% and 87.5%, respectively) or low grade Gleason 6 prostate cancer (13.8% and 12.5%, respectively) on lesion-specific targeted biopsies. These lesions demonstrated no significant change in size (P = 0.93 and P = 0.36) over a mean imaging period of 2.31±1.56 years and 2.40±1.77 years for ≤7 mm and ≤5 mm index lesion thresholds, respectively. These findings held true on subset analyses of patients who had a minimum of two-year interval follow-up with MP-MRI.
Conclusion: Small index lesions of the prostate are pathologically benign lesions or occasionally low-grade cancers. Slow growth rate of these small index lesions on serial MP-MRI suggests a surveillance interval of at least two years without significant change.
Figures



Similar articles
-
Multiparametric MRI in detection and staging of prostate cancer.Dan Med J. 2017 Feb;64(2):B5327. Dan Med J. 2017. PMID: 28157066 Review.
-
Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.Eur Radiol. 2020 Nov;30(11):6042-6051. doi: 10.1007/s00330-020-06997-1. Epub 2020 Jun 26. Eur Radiol. 2020. PMID: 32591887 Free PMC article.
-
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance.BJU Int. 2013 Jun;111(7):1037-45. doi: 10.1111/j.1464-410X.2012.11641.x. Epub 2013 Mar 6. BJU Int. 2013. PMID: 23464904 Free PMC article. Clinical Trial.
-
Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.Eur Urol Focus. 2019 May;5(3):407-415. doi: 10.1016/j.euf.2017.12.008. Epub 2018 Jan 10. Eur Urol Focus. 2019. PMID: 29331622
-
Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.Invest Radiol. 2014 Mar;49(3):165-72. doi: 10.1097/RLI.0000000000000008. Invest Radiol. 2014. PMID: 24220253
Cited by
-
Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance.Front Oncol. 2017 Oct 30;7:256. doi: 10.3389/fonc.2017.00256. eCollection 2017. Front Oncol. 2017. PMID: 29164056 Free PMC article. Review.
-
Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.Balkan Med J. 2017 Sep 29;34(5):388-396. doi: 10.4274/balkanmedj.2017.0708. Balkan Med J. 2017. PMID: 28990929 Free PMC article.
-
Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.Urol Oncol. 2015 May;33(5):202.e1-202.e7. doi: 10.1016/j.urolonc.2015.01.023. Epub 2015 Mar 6. Urol Oncol. 2015. PMID: 25754621 Free PMC article.
-
Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension.Prostate Cancer Prostatic Dis. 2015 Mar;18(1):81-5. doi: 10.1038/pcan.2014.50. Epub 2015 Jan 6. Prostate Cancer Prostatic Dis. 2015. PMID: 25559097
-
Functional MRI in prostate cancer detection.Biomed Res Int. 2014;2014:590638. doi: 10.1155/2014/590638. Epub 2014 Jul 23. Biomed Res Int. 2014. PMID: 25215284 Free PMC article. Review.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
-
- Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101:894–904. - PubMed
-
- Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933–938. - PubMed
-
- Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–374. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical